COVID-19：中国初のmRNAワクチンを10月量産開始：年間で2億回（動画）：
China’s mRNA vaccine to enter production in Oct with annual 200 mil doses：
我国首个自主研发的mRNA疫苗10月进入量产 年产能2亿剂
ARCoVax：
「中国初のmRNAワクチン・ARCoVaxの生産」が開始します。
国産のコア原材料と設備を使用し、10月に量産開始の予定。
軍事医学研究院：
中国は、コアmRNAワクチンの技術を掌握しています。
mRNAワクチンの開発は、国の集団予防接種推進力を向上します。
軍事医学研究院が共同開発したとのこと。
ARCoVax：
蘇州アボゲンとYunnan Walvax Biotechnology が、
「ARCoVaxと呼ばれるmRNAワクチンの生産」を担当します。
来月、中国南西部の雲南省玉渓市の拠点で量産を開始する予定。
With an investment of 520 million yuan ($80 million), the plant, China’s first production base for mRNA vaccine,
has the capacity to produce 200 million doses annually.
Compared with mRNA vaccines developed by the US and Germany,
the domestic mRNA vaccine is much safer as the selection of the vaccine antigen target is more precise and the neutralizing antibodies induced are higher,
media reports said.
The storage cost of this vaccine
is lower than those from overseas as it adopts a single injection in one package
and could be stored at room temperature for a week or at 4 C for a long time, making it easier to use.
A Beijing-based immunologist told the Global Times on Thursday that
the domestically produced mRNA vaccine demonstrates China’s huge improvements in mRNA technology and the country’s leading position in biotechnology.
ARCoVax has been approved to initiate its late-stage clinical trials in Mexico and Indonesia
by local health authorities, Yunnan Walvax Biotechnology Co announced on August 31.
Global Times
https://www.globaltimes.cn/page/202109/1233797.shtml
Mexico to start late-stage clinical trial for China’s mRNA COVID-19 vaccine
MEXICO CITY (Reuters)
Mexico plans to start a late-stage clinical trial this month for a COVID-19 vaccine candidate developed by China using similar technology to shots from Moderna and Pfizer,foreign minister Marcelo Ebrard said on Tuesday.
The phase III trial for the shot from China’s Walvax Biotechnology using messenger RNA (mRNA) technology will start on May 30 and involve 6,000 volunteers, Ebrard said in a Tweet.
https://ca.movies.yahoo.com/mexico-start-phase-iii-clinical-123058946.html